# Early Access Program of Lazertinib in Republic of Korea

> **NCT04829422** · — · APPROVED_FOR_MARKETING · sponsor: **Yuhan Corporation**

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Lazertinib 240 mg

## Key facts

- **NCT ID:** NCT04829422
- **Lead sponsor:** Yuhan Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2022-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04829422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04829422, "Early Access Program of Lazertinib in Republic of Korea". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04829422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*